Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway

Mol Med Rep. 2014 Apr;9(4):1254-8. doi: 10.3892/mmr.2014.1956. Epub 2014 Feb 17.

Abstract

Clinically, diabetes mellitus is closely associated with and induces certain cardiovascular diseases. The aim of this study was to investigate endoplasmic reticulum (ER) stress-associated apoptosis of diabetic cardiomyopathy (DCM), and explore the protective mechanism of liraglutide. The DCM model was established with a high-fat diet and streptozotocin (STZ). Cardiac function was detected by echocardiogram examination and hematoxylin-eosin staining. ER stress unfolded protein response (UPR) hallmarks [inositol-requiring enzyme-α (IRE-α), p-Perk and ATF6] and transcription factors were detected with western blotting. Apoptosis inducers CHOP, c-Jun amino terminal kinase (JNK) and casapse-12 were also examined with western blotting. The results indicated that liraglutide is capable of improving cardiac function in DCM rats (P<0.05). IRE-α expression was significantly increased in the DCM group compared with the control group (P<0.05), and liraglutide is capable of decreasing IRE-α expression. X-box transcription factor-1 (XBP-1) was significantly spliced in the model group, and downregulated in the liraglutide-treated group. CHOP protein was upregulated in the DCM group, but inactivated by liraglutide treatment. In conclusion, liraglutide is capable of protecting DCM and blocking CHOP-mediated ER stress by inhibiting the IRE-α UPR pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis* / drug effects
  • Blood Glucose / metabolism
  • Diabetic Cardiomyopathies / blood
  • Diabetic Cardiomyopathies / diagnostic imaging
  • Diabetic Cardiomyopathies / drug therapy*
  • Diabetic Cardiomyopathies / pathology*
  • Disease Models, Animal
  • Electrocardiography
  • Endoplasmic Reticulum Stress / drug effects
  • Endoribonucleases / metabolism*
  • Fasting / blood
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / pharmacology
  • Glucagon-Like Peptide 1 / therapeutic use
  • Liraglutide
  • Male
  • Mice
  • Multienzyme Complexes / metabolism*
  • Myocardium / metabolism
  • Myocardium / pathology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Protein Serine-Threonine Kinases / metabolism*
  • Rats
  • Rats, Wistar
  • Signal Transduction* / drug effects
  • Transcription Factor CHOP
  • Ultrasonography

Substances

  • Blood Glucose
  • Ern1 protein, rat
  • Multienzyme Complexes
  • Transcription Factor CHOP
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Protein Serine-Threonine Kinases
  • Endoribonucleases